MISSISSAUGA, Ontario, Oct. 15, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen“) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to announce that it has successfully completed an extended durability test of its GEN2 electrolysis cells used in the efficient production of green hydrogen. The GEN2 cells will […]
Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Oct. 15, 2024 (GLOBE NEWSWIRE) — Koryx Copper Inc. (“Koryx” or the “Company“) (TSX-V: KRY) is pleased to announce that it has closed the first tranche (the “First Tranche“) of the previously announced non-brokered private placement (the “Offering”)
RICHARDSON, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) (the “Company”) today announced that it is granting an equity award as a material inducement to the employment of the Company’s newly-hired Chief Executive Officer, Franco Fogliato. In connection with the appointment of Mr. Fogliato as Chief Executive Officer effective September 18,
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome
Operational Highlights Work continued on the Airbus-sponsored project to benchmark HT-PEM fuel cell MEAs in aviation for the second quarter. The project continued as planned without delays. Met milestones with the U.S. Department of Defense on two previously awarded contracts for portable power systems. Continued Technology Assessment Work for four of the largest 15 automotive
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting,
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the presentation of data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG) during the 2024 Myasthenia Gravis Foundation of America (MGFA)
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trials in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2024 fourth quarter results after the close of trading
Operational Highlights Started work on the Joint Project with Airbus to benchmark HT-PEM fuel cell MEAs in aviation. Continued work with the U.S. Department of Defense on two previously awarded contracts for portable power systems. Continued Technology Assessment Work for four of the largest 15 automotive manufacturers in the world. Continued streamlining of operations process